These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Author: Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM.
    Journal: N Engl J Med; 1998 Jun 18; 338(25):1793-7. PubMed ID: 9632445.
    Abstract:
    BACKGROUND: Idiopathic cerebral-vein thrombosis can cause serious neurologic disability. We evaluated risk factors for this disorder, including genetic risk factors (mutations in the genes encoding factor V and prothrombin) and nongenetic risk factors (such as the use of oral contraceptive agents). We compared the prevalence of these risk factors in 40 patients with cerebral-vein thrombosis, 80 patients with deep-vein thrombosis of the lower extremities, and 120 healthy controls. The G1691A mutation in the factor V gene and the G20210A prothrombin-gene mutation, which are established genetic risk factors for venous thrombosis, were studied. We also assessed the use of oral contraceptives and other risk factors for thrombosis. RESULTS: The prevalence of the prothrombin-gene mutation was higher in patients with cerebral-vein thrombosis (20 percent) than in healthy controls (3 percent; odds ratio, 10.2; 95 percent confidence interval, 2.3 to 31.0) and was similar to that in patients with deep-vein thrombosis (18 percent). Similar results were obtained for the mutation in the factor V gene. The use of oral contraceptives was more frequent among women with cerebral-vein thrombosis (96 percent) than among controls (32 percent; odds ratio, 22.1; 95 percent confidence interval, 5.9 to 84.2) and among those with deep-vein thrombosis (61 percent; odds ratio, 4.4; 95 percent confidence interval, 1.1 to 17.8). For women who were taking oral contraceptives and who also had the prothrombin-gene mutation (seven patients with cerebral-vein thrombosis but only one control), the odds ratio for cerebral-vein thrombosis rose to 149.3 (95 percent confidence interval, 31.0 to 711.0). CONCLUSIONS: Mutations in the prothrombin gene and the factor V gene are associated with cerebral-vein thrombosis. The use of oral contraceptives is also strongly and independently associated with the disorder. The presence of both the prothrombin-gene mutation and oral-contraceptive use raises the risk of cerebral-vein thrombosis further. The role of the prothrombin-gene mutation in idiopathic cerebral-vein thrombosis and its interaction with other risk factors was investigated in a study of 40 patients (9 men and 31 women) 15-64 years of age who presented to a thrombosis center in Milan, Italy, in 1991-97 after a first episode of this thrombosis. Also enrolled were 80 men and women randomly selected from patients screened at the same center during the study period after a first documented episode of proximal deep-vein thrombosis of the lower extremities. 120 healthy controls were matched to cerebral-vein thrombosis patients by sex, age, geographic origin, and education. 20% of patients with cerebral-vein thrombosis (odds ratio (OR), 10.2; 95% confidence interval (CI), 2.3-31.0), 18% of those with deep-vein thrombosis, and 3% of controls were carriers of the prothrombin-gene mutation. Factor V mutation was more prevalent in patients with cerebral-vein thrombosis (15%) than controls (3%) (OR, 7.8; 95% CI, 1.8-34.1), but the thrombotic risks associated with these two mutations were independent of each other. Oral contraceptive (OC) ever-use was more frequent among women with cerebral-vein thrombosis (96%) (OR, 22.1; 95% CI, 5.9-84.2) and deep-vein thrombosis (61%) (OR, 4.4; 95% CI, 1.1-17.8) compared with controls (32%). For the 7 women with cerebral-vein thrombosis who were both OC ever-users and had the prothrombin-gene mutation, the thrombotic risk rose to 149.3 (95% CI, 31.0-711.0). These findings show that there is a hypercoagulable state in 35% of patients with idiopathic cerebral-vein thrombosis. Although screening for the prothrombin-gene mutation in young women before they are prescribed OCs is unlikely to be cost-effective, carriers of the mutation who have had a thrombosis episode should discontinue OC use.
    [Abstract] [Full Text] [Related] [New Search]